OBJECTIVES: Treatment of the pain caused by chronic pancreatitis (CP) is not standardized. Knowledge of the response to placebo in this setting may aid the design of future trials. We aimed at investigating the placebo effect on abdominal pain remission rates in patients with CP. METHODS: MEDLINE, EMBASE, and Scopus were searched, and randomized placebo-controlled trials in CP providing data on abdominal pain remission rates in placebo arms were included. Pooled estimates of the placebo rate were calculated using random-effects logistic regression analysis. Stratum-specific rates for different patients and study-level covariates were calculated to account for heterogeneity. RESULTS: Seven randomized controlled trials (202 placebo-treated patients) met the predefined criteria. The pooled estimate of the placebo rate for pain remission was 19.9% (95% confidence interval, 9%-36%). There was a statistically significant heterogeneity among the studies (I(2) = 76%; P < 0.001). A multicenter design, a run-in period of less than 2 weeks, and absence of a washout in crossover trials were all significant sources of heterogeneity associated with higher placebo responses. CONCLUSIONS: This meta-analysis identifies for the first time the efficacy of placebo for pain in CP and variables determining it. These data provide a sound basis for designing future placebo-controlled randomized clinical trials for the treatment of pain in CP.
OBJECTIVES: Treatment of the pain caused by chronic pancreatitis (CP) is not standardized. Knowledge of the response to placebo in this setting may aid the design of future trials. We aimed at investigating the placebo effect on abdominal pain remission rates in patients with CP. METHODS: MEDLINE, EMBASE, and Scopus were searched, and randomized placebo-controlled trials in CP providing data on abdominal pain remission rates in placebo arms were included. Pooled estimates of the placebo rate were calculated using random-effects logistic regression analysis. Stratum-specific rates for different patients and study-level covariates were calculated to account for heterogeneity. RESULTS: Seven randomized controlled trials (202 placebo-treated patients) met the predefined criteria. The pooled estimate of the placebo rate for pain remission was 19.9% (95% confidence interval, 9%-36%). There was a statistically significant heterogeneity among the studies (I(2) = 76%; P < 0.001). A multicenter design, a run-in period of less than 2 weeks, and absence of a washout in crossover trials were all significant sources of heterogeneity associated with higher placebo responses. CONCLUSIONS: This meta-analysis identifies for the first time the efficacy of placebo for pain in CP and variables determining it. These data provide a sound basis for designing future placebo-controlled randomized clinical trials for the treatment of pain in CP.
Authors: Michelle A Anderson; Venkata Akshintala; Kathryn M Albers; Stephen T Amann; Inna Belfer; Randall Brand; Suresh Chari; Greg Cote; Brian M Davis; Luca Frulloni; Andres Gelrud; Nalini Guda; Abhinav Humar; Rodger A Liddle; Adam Slivka; Rachelle Stopczynski Gupta; Eva Szigethy; Jyothsna Talluri; Wahid Wassef; C Mel Wilcox; John Windsor; Dhiraj Yadav; David C Whitcomb Journal: Pancreatology Date: 2015-11-11 Impact factor: 3.996
Authors: Christopher E Forsmark; Dana K Andersen; John T Farrar; Megan Golden; Aida Habtezion; Sohail Z Husain; Liang Li; Julia Mayerle; Stephen J Pandol; Aliye Uc; Zixi Zhu; Dhiraj Yadav Journal: Pancreas Date: 2018 Nov/Dec Impact factor: 3.327
Authors: Marjan de Vries; Dagmar C M Van Rijckevorsel; Kris C P Vissers; Oliver H G Wilder-Smith; Harry Van Goor Journal: Br J Clin Pharmacol Date: 2016-01-17 Impact factor: 4.335
Authors: Stefan Aw Bouwense; Søren S Olesen; Asbjørn M Drewes; Harry van Goor; Oliver Hg Wilder-Smith Journal: J Pain Res Date: 2015-07-10 Impact factor: 3.133
Authors: Gianluca Castelnuovo; Emanuele Maria Giusti; Gian Mauro Manzoni; Donatella Saviola; Samantha Gabrielli; Marco Lacerenza; Giada Pietrabissa; Roberto Cattivelli; Chiara Anna Maria Spatola; Alessandro Rossi; Giorgia Varallo; Margherita Novelli; Valentina Villa; Francesca Luzzati; Andrea Cottini; Carlo Lai; Eleonora Volpato; Cesare Cavalera; Francesco Pagnini; Valentina Tesio; Lorys Castelli; Mario Tavola; Riccardo Torta; Marco Arreghini; Loredana Zanini; Amelia Brunani; Ionathan Seitanidis; Giuseppe Ventura; Paolo Capodaglio; Guido Edoardo D'Aniello; Federica Scarpina; Andrea Brioschi; Matteo Bigoni; Lorenzo Priano; Alessandro Mauro; Giuseppe Riva; Daniele Di Lernia; Claudia Repetto; Camillo Regalia; Enrico Molinari; Paolo Notaro; Stefano Paolucci; Giorgio Sandrini; Susan Simpson; Brenda Kay Wiederhold; Santino Gaudio; Jeffrey B Jackson; Stefano Tamburin; Fabrizio Benedetti Journal: Front Neurol Date: 2018-05-18 Impact factor: 4.003
Authors: Søren S Olesen; Asbjørn M Drewes; Rajesh Gaud; Manu Tandan; Sundeep Lakhtakia; Mohan Ramchandani; G V Rao; D Nageshwar Reddy; Rupjyoti Talukdar Journal: Trials Date: 2020-04-16 Impact factor: 2.279